Deng Xingwang, Chen Qian, Qiang Lijuan, Chi Mingwei, Xie Nan, Wu Yinsheng, Yao Ming, Zhao Dan, Ma Jiaxiang, Zhang Ning, Xie Yan
College of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
Department of Burns and Plastic Surgery, Xinyang Central Hospital, Xinyang, China.
Front Pharmacol. 2018 Jun 5;9:590. doi: 10.3389/fphar.2018.00590. eCollection 2018.
Hypertrophic scars formed after burns remain a challenge in clinical practice. Development of effective scar therapies relies on validated animal models that mimic human hypertrophic scars. A consistent porcine full-thickness burn hypertrophic scar model has yet to be developed. We have previously reported that Shikonin induces apoptosis and reduces collagen production in hypertrophic scar fibroblasts and may therefore hold potential as a novel scar remediation therapy. In this study, we aimed to validate the potential of Shikonin on scar remediation . A novel porcine hypertrophic scar model was created after full-thickness burn wounds, and the effect of Shikonin on scar remediation was investigated. Clinical scar assessments, histology, and immunohistochemistry were used to evaluate scar appearance, morphology, and protein expression. Eight weeks after scar formation, clinical scar assessment indicated that the score of hypertrophic scars treated with Shikonin was significantly lower than that of the control group. Hypertrophic scars treated with Shikonin appeared flat, pink, and pliable. In addition, histological analysis indicated that hypertrophic scars treated with Shikonin exhibited reduced thickness of the epidermis and dermis, thin and even epithelial layers, reduced numbers of keratinocytes, uniform distribution of fibroblasts, and a parallel and loose arrangement of collagen fibers in the dermis. Moreover, immunohistochemical analysis indicated that Shikonin inhibited the expression of p63, cytokeratin 10, alpha-smooth muscle actin, transforming growth factor-beta 1, and collagen I, which play important roles in hypertrophic scar formation. Based on these results, we conclude that Shikonin has potential as a novel scar therapy.
烧伤后形成的增生性瘢痕仍是临床实践中的一个挑战。有效的瘢痕治疗方法的开发依赖于能够模拟人类增生性瘢痕的经过验证的动物模型。目前尚未开发出一种一致的猪全层烧伤增生性瘢痕模型。我们之前曾报道,紫草素可诱导增生性瘢痕成纤维细胞凋亡并减少胶原蛋白生成,因此可能具有作为新型瘢痕修复疗法的潜力。在本研究中,我们旨在验证紫草素在瘢痕修复方面的潜力。在全层烧伤创面后创建了一种新型猪增生性瘢痕模型,并研究了紫草素对瘢痕修复的影响。采用临床瘢痕评估、组织学和免疫组织化学方法来评估瘢痕外观、形态和蛋白表达。瘢痕形成8周后,临床瘢痕评估表明,用紫草素治疗的增生性瘢痕评分显著低于对照组。用紫草素治疗的增生性瘢痕显得扁平、呈粉红色且质地柔韧。此外,组织学分析表明,用紫草素治疗的增生性瘢痕表皮和真皮厚度减小,上皮层薄且均匀,角质形成细胞数量减少,成纤维细胞分布均匀,真皮中胶原纤维平行且排列疏松。而且,免疫组织化学分析表明,紫草素抑制了p63、细胞角蛋白10、α-平滑肌肌动蛋白、转化生长因子-β1和I型胶原的表达,这些蛋白在增生性瘢痕形成中起重要作用。基于这些结果,我们得出结论,紫草素具有作为新型瘢痕治疗方法的潜力。